All issues in this bulletin series

If you're having trouble viewing this email, you may see it online.

April 20, 2018

Research Grant Opportunities

In This Issue...

PRE-ANNOUNCEMENT: NETWORK GRANT ON GLOBAL GOVERNANCE FOR INFECTIOUS DISEASE

PRE-ANNOUNCEMENT: The Canadian Institutes of Health Research (CIHR)

PRE-ANNOUNCEMENT: The Canadian Institutes of Health Research (CIHR)

Call for Stories: Canada Exhibit at International AIDS Conference 2018

NATIONAL GRANT OPPORTUNITY - CENTRE FOR AGING + BRAIN HEALTH INNOVATION

NATIONAL GRANT OPPORTUNITY – CIHR- Operating Grant : AMR: Point of Care Diagnostics in Human Health - Phase 2

NATIONAL GRANT OPPORTUNITY - NSERC – COLLABORATIVE RESEARCH AND TRAINING EXPERIENCE PROGRAM (CREATE) COMPETITION 2018

NATIONAL GRANT OPPORTUNITY – CIHR - The Antimicrobial Resistance Initiatives, under the scientific leadership of the Institute of Infection and Immunity and the Institute of Population and Public Health

NATIONAL GRANT OPPORTUNITY – The CIHR Institute of Genetics (CIHR-IG) and the CIHR Institute of Nutrition, Metabolism and Diabetes (INMD) in partnership with Genome Canada

FELLOWSHIP FUNDING OPPORTUNITIES/ANNOUNCEMENTS: CSHP Fellow Program

AWARDS- Canadian Orthopaedic Foundation - Community Innovation Award

TRAVEL AWARDS – Canadian Institute of Health Research CIHR

PRE-ANNOUNCEMENT: NETWORK GRANT ON GLOBAL GOVERNANCE FOR INFECTIOUS DISEASE

This Network Grant aims to foster research collaborations on developing global governance arrangements and best practices for managing public health threats and infectious diseases. The Network Grant is meant to facilitate the creation of an interdisciplinary Canadian research network that can generate and apply new knowledge about effective global governance for health. Full details for this opportunity are anticipated to be available on ResearchNet starting early May 2018. The Institute of Population and Public Health and III will provide further information about this opportunity closer to the launch date.

PRE-ANNOUNCEMENT: The Canadian Institutes of Health Research (CIHR)

The Canadian Institutes of Health Research (CIHR) Institute of Infection and Immunity (III) and the CIHR HIV/AIDS Research Initiative are pleased to announce the upcoming launch of a new Request for Applications (RFA) for HIV/AIDS Biomedical and Clinical Team Grants in May 2018.

Program Launch: May 2018
Application Deadline: November 2018

Funding Amount:
• The total amount available for this funding opportunity is $20,000,000, enough to fund approximately 6 grants. This amount may increase if additional funding partners participate.
• Of this $20M:

¨       $8M is available for focused team grants, enough to fund 4 grants (2 in "From Control to Cure" and 2 in "Biomedical Prevention").

¨       $12M is available for large team grants, enough to fund 2 grants (1 in "From Control to Cure" and 1 in "Biomedical Prevention").

• For focused teams the maximum amount per grant is $400,000 per year for up to five years for the team grants.
• For the large teams the maximum amount per grant is $1,200,000 per year for up to five years for the large team grants.

Description
The focused teams must involve a minimum of three investigators and may work in areas of higher risk.
The large teams, with a minimum of 8 investigators from at least three provinces or territories including at least one New Investigator and one mid-career investigator, will bring together experts from different disciplines working collaboratively on a number of inter-related research projects under a unified program of research.

To ensure teams are well positioned not only to generate important new knowledge but to also apply it in timely fashion, programs must include a strong core of basic scientists and clinical investigators. These teams must discuss training plans in order to build further capacity for HIV research and stimulate innovative approaches. They must also consider the relevance of their work to people living with HIV and its ethical implications and, therefore, must include relevant stakeholders in the oversight of the program of research.

Objectives
The Team Grant HIV/AIDS Biomedical and Clinical Research is expected to contribute to the global search for a safe and effective cure for HIV, and to develop prevention strategies and tools.

The specific objectives of this funding opportunity are to:

• transform HIV biomedical and clinical research in Canada into a collaborative, interdisciplinary model of knowledge creation and application through the funding of innovative research programs;
• create an inclusive and sustainable pipeline of HIV research capacity from across disciplines, sectors, and perspectives (e.g., HIV basic scientists, clinical investigators, knowledge users and/or community members (people living with HIV));
• effectively translate knowledge into clinical and/or commercial applications which contribute to the design, development and evaluation of research strategies; and
• create a critical mass of technical and scientific expertise in Canada that engages meaningfully with one another, relevant national stakeholders and international research efforts.

Research Areas
This funding opportunity will support projects relevant to the following research areas. It is not expected that programs will address all of the priority areas listed below, but rather, that they will target one of the following two priority areas.

From Control to Cure

¨       Molecular, cellular, immunological and viral mechanisms to HIV persistence and latency

¨       Immune based therapies to clear HIV

¨       Develop and exploit cell or gene therapy for HIV Cure

¨       Biomarkers identification, development and validation for HIV persistence

¨       Research and development of latency reversing agents

¨       Cellular and animal models of HIV latency

¨       Analysis of viral reservoir when on antiretroviral therapy (ART)

• Biomedical Prevention

¨       Immune based strategies to HIV prevention (can target any of the following : mucosal, innate, humoral or cellular immunity; immune correlates of prevention)

¨       Preventive Vaccines, novel adjuvants, and new technologies to expedite vaccine development

¨       Microbicides

¨       Microbiome based HIV prevention strategies

¨       HIV medication to prevent transmission (treatment as prevention; pre- and post-exposure prophylaxis)

¨       Biomedical and clinical interventions  and evaluations of preventive strategies

The complete RFA will be posted on ResearchNet by the end of May 2018.

Contact information
CIHR Contact Centre at 613-954-1968 or
support@cihr-irsc.gc.ca

PRE-ANNOUNCEMENT: The Canadian Institutes of Health Research (CIHR)

The Canadian Institutes of Health Research (CIHR) Institute of Infection and Immunity (III) and the CIHR HIV/AIDS Research Initiative in partnership with the CIHR Institute of Indigenous Peoples’ Health, CIHR Institute of Population and Public Health and the CIHR Institute of Health Services and Policy Research are pleased to announce the upcoming launch of a new Request for Applications (RFA) for Centres for HIV/AIDS, Hepatitis C and other STBBIs Population Health and Health Services Research in May 2018.

Anticipated Timelines
• Program Launch: May 2018
• Application Deadline: December 2018

Funds Available
• The total amount available for this funding opportunity is $10,000,000, enough to fund approximately two to three grants. This amount may increase if additional funding partners participate. Centres may be variable in size, it is anticipated that requested budgets will range from $400,000 to $1,000,000 per annum. The maximum amount per grant is $1,000,000 per year for up to 5 years for a total of $5,000,000, per grant. Approved grants may receive an across-the-board cut to the budget, if necessary, to maximize the number of funded opportunities.

• Of this $10,000,000:

  • A maximum of $5,000,000 is available to fund applications relevant to support at least one application that focuses exclusively on First Nations, Inuit, Métis and/or Urban Indigenous populations. Note that should no Indigenous Stream applications be deemed fundable, these funds will be transferred to the General (non-Indigenous) Stream

Description
The Centres for HIV/AIDS Population Health and Health Services Research program was originally launched in 2007 and was re-launched in 2013.

The Centres for HIV/AIDS, Hepatitis C and other STBBIs Population Health and Health Services Research program (the Centres) will continue to provide core infrastructure funding for multi-jurisdictional and multidisciplinary teams of researchers and their stakeholders. The funded Centres will specialize in population health and health services and policy research and capacity building as it pertains to HIV, Hepatitis C and other STBBIs.

The Centres will mobilize the talent, expertise and capacity of different sectors and jurisdictions to solve current and emerging challenges with the ongoing transmission of HIV and for people living with HIV in Canada.

The Centres are expected to work with one another and other relevant regions, networks and partners in order to minimize duplication of efforts and maximize impacts and contributions to reductions in HIV transmission and improved health outcomes for Canadians.

Objectives
The Centres for HIV/AIDS, Hepatitis C and other STBBIs Research are expected to improve health and access to effective programs and services for people living with and at risk of HIV, Hepatitis C and other STBBIs, particularly for populations most affected. The specific objectives of the Centres are to:

• foster coordination of research efforts by developing and supporting a network of collaborative Centres for Population Health and Health Services Research Development in HIV, Hepatitis C and other STBBIs;
• develop and/or strengthen high quality infrastructure for implementation science, health services and population health research to enable Canadian HIV, Hepatitis C and other STBBI researchers to conduct innovative, high quality, collaborative research;
• facilitate implementation science, health services and population health research training and mentoring initiatives to strengthen the capacity of trainees; and
• accelerate the translation and uptake of knowledge and implementation of evidence to inform practices, policies and programs through models of integrated knowledge translation and innovative strategies that engage stakeholders and partners (including people living with HIV, community organizations, clinicians, policy makers and relevant networks).

Research Areas
The CIHR HIV/AIDS Research Initiative will provide funding for Centres that address the relevant research areas described below. Centres are expected to be strategic and focused in their efforts and have impact in each of the following areas:

• HIV, Hepatitis C and other STBBI  Prevention and Management: Research and capacity building to develop and evaluate innovative models for preventing, managing and treating individuals and populations at risk of developing or living with disease(s).
• Access to Appropriate testing, Diagnosis and Care for Vulnerable Populations: Research and capacity building to develop and evaluate innovative models to improve equity of access to appropriate testing, diagnosis and care by focusing on vulnerable subgroups who are at greater risk of poorer health outcomes and experiencing challenges in equity of access, and by addressing individual, social and structural determinants of health that lead to or reinforce conditions of vulnerability (e.g., stigmatization, migration).

To Learn More
The complete RFA will be posted on ResearchNet by the end of May 2018.

Contact information
CIHR Contact Centre at 613-954-1968 or support@cihr-irsc.gc.ca

Call for Stories: Canada Exhibit at International AIDS Conference 2018

The Canadian Society for International Health (CSIH) wants to showcase Canadian HIV/AIDS stories. This year the 22nd International AIDS Conference (AIDS 2018), hosted in Amsterdam, Netherlands from July 23 to 27, will highlight the theme “Breaking Barriers, Building Bridges.”


The CSIH is pleased to be developing and coordinating activities for the Canada Exhibit at AIDS 2018. The Canada Exhibit will showcase research, best practices, achievements, and challenges met and overcome in the Canadian response to HIV/AIDS. As part of our efforts to highlight the reality of people with lived experience of HIV/AIDS, and people who work in the field, CSIH is looking for story submissions, in the form of text, photos and/or video.  Stories must be submitted by April 27, 2018.
Read more on Canada Exhibit at International AIDS Conference 2018 and Call for Stories.

NATIONAL GRANT OPPORTUNITY - CENTRE FOR AGING + BRAIN HEALTH INNOVATION

Title: 2018 Call for Innovations: Researcher- Clinician Partnership Program – Round 3

Sponsor: The Centre for Aging + Brain Health Innovation’s (CABHI)

Funding Amount:up to $500,000

Application Deadline: May 18, 2018, 5:00 pm EST

ORS Deadline: May 11, 2018

ORS Contact: Michelina Violi, Research Grant Officer (Health), Michelina.Violi@umanitoba.ca

Link: http://www.cabhi.com/rcp2-2018-round3/

CABHI supports innovations that address challenges associated with the aging brain, including dementia and other neurodegenerative diseases. In 2018, CABHI’s focus will be on testing innovative solutions that are aimed at addressing the specific themes listed below:

  1. Aging in place: solutions that enable older adults with dementia to maximize their choice, independence and quality of life regarding where they live
  2. Caregiver support: solutions that support caregivers (formal and informal) in providing care to older adults with dementia
  3. Care coordination and navigation: solutions that help older adults, caregivers and healthcare providers coordinate care and transitions for older adults with dementia
  4. Cognitive health: solutions focused on health promotion, prevention, early diagnostics, and slowing the progression of cognitive impairment in aging adults.

All project applications must focus on one or more of these themes. Applicants must apply as a team composed of at least one researcher and one clinician working jointly on study design, trial implementation, data collection, analysis and reporting.

NATIONAL GRANT OPPORTUNITY – CIHR- Operating Grant : AMR: Point of Care Diagnostics in Human Health - Phase 2

Title: Operating Grant : AMR: Point of Care Diagnostics in Human Health - Phase 2

Sponsor: The Antimicrobial Resistance Initiatives, under the scientific leadership of the Institute of Infection and Immunity and the Institute of Population and Public Health

Deadline: August 15, 2018

Funding Amount: The maximum amount per grant is $225,000 per year for up to 3 years for a total of $675,000 per grant.

Telephone: 613-954-1968
Toll Free: 1-888-603-4178
Email: support@cihr-irsc.gc.ca

Link: https://www.researchnet-recherchenet.ca/rnr16/vwOpprtntyDtls.do?all=1&masterList=true&next=1&org=CIHR&prog=2846&resultCount=25&sort=program&type=EXACT&view=currentOpps&language=E

CIHR has launched Phase 2 of the AMR: POC Diagnostics in Humam Health program competition, which aims to further accelerate development of technologies or tools that have passed the preliminary design developmental phase. Phase 2 is open to Phase 1 and any others that meet the eligibility criteria. The main goal of this funding opportunity is to further facilitate and improve the development of clinically relevant point-of-care diagnostic tools in AMR that will improve rational use of antibiotics and improve clinical management.

Research Areas

This funding opportunity will support projects relevant to any of the following research areas:

•Projects that have a human health focus at the patient or bedside level (adult and/or pediatric).

•Diagnostic tools that distinguish bacterial from viral infections (e.g. host biomarkers, multiplex, etc.) both qualitatively or quantitatively.

•Pathogen (bacteria, viruses, fungi, parasites)-specific diagnostics, providing information on susceptibility/resistance to antimicrobial agents.

•Diagnostic tools that permit at least one of the following: ◦a shorter time-to-result identification of specific infectious agent and their resistance profile;

◦an increased sensitivity and/or simplicity of test or allow for more minimally invasive specimen collection;

◦a facilitated communication of results to healthcare provider or public health practitioner; and

◦a rapid diagnostics for resource-limited settings.

 

•Evaluations of POC testing for AMR in different settings.

•Studies on feasibility, acceptability, change in policies for the introduction of POC tests for detecting resistance microbial pathogens.

NATIONAL GRANT OPPORTUNITY - NSERC – COLLABORATIVE RESEARCH AND TRAINING EXPERIENCE PROGRAM (CREATE) COMPETITION 2018

Title: NSERC – Collaborative Research and Training Experience Program (CREATE) Competition 2018

Sponsor: Natural Sciences And Engineering Research Council Of Canada (NSERC)

Funding Amount: Up to $150,000 in the first year and up to $300,000 for up to five subsequent years, for a maximum of $1.65M over 6 years.

Agency Letter of Intent deadline: 1 May 2018

ORS Letter of Intent deadline: 17 April 2018

Agency full application deadline: 22 September 2018 (upon invitation)

ORS full application deadline: 8 September 2018

This program supports the training of teams of highly qualified students and postdoctoral fellows from Canada and abroad through the development of innovative training programs that:

encourage collaborative and integrative approaches, and address significant scientific challenges associated with Canada’s research priorities;

facilitate the transition of new researchers from trainees to productive employees in the Canadian workforce.

Funding of $150,000 in the first year (± $50,000) and $300,000 (± $50,000) annually for up to five subsequent years will be provided by NSERC for up to $1.65 million dollars over six years. At least 80% of the CREATE grant must be used for trainees’ stipends.

Applicants are encouraged, but not required, to submit training programs that fall within Canada’s research strengths and priorities under NSERC priority areas:

  • Environmental science and technologies;
  • Natural resources and energy;
  • Manufacturing;
  • Information and communications technologies.

The LOI stage is mandatory for all applications to the CREATE program. Specific instructions for the Form 187 (CREATE LOI) can be found here. NSERC CREATE Webinar materials (slides; presentation recording) can be found here.

 

Please note that this LOI requires a letter of support from VPRIO – researchers who intend to submit a CREATE LOI in 2018 must discuss their plans with their Associate Dean (Research) well in advance of the ORS internal deadline.

NATIONAL GRANT OPPORTUNITY – CIHR - The Antimicrobial Resistance Initiatives, under the scientific leadership of the Institute of Infection and Immunity and the Institute of Population and Public Health

Title: Operating Grant : AMR: Point of Care Diagnostics in Human Health - Phase 2

Sponsor: The Antimicrobial Resistance Initiatives, under the scientific leadership of the Institute of Infection and Immunity and the Institute of Population and Public Health

Funding Amount: The maximum amount per grant is $225,000 per year for up to 3 years for a total of $675,000 per grant.

Application Deadline: August 15, 2018

ORS Deadline: August 8, 2018

ORS Contact: Bryn Jones Square, Research Grants Office (CIHR), bryn.jonessquare@umanitoba.ca

Link: https://www.researchnet-recherchenet.ca/rnr16/vwOpprtntyDtls.do?prog=2846&view=currentOpps&org=CIHR&type=EXACT&resultCount=25&sort=program&next=1&all=1&masterList=true

Antimicrobial resistance (AMR) is a serious and growing global public threat that requires a global unified response. Governments and health organizations around the world are increasingly paying more attention to the significant threat that AMR poses to modern medicine and the health of the global population. In Canada and around the world, the effectiveness of antimicrobials has been declining due to the development of resistance.

The CIHR AMR initiative aligns with the research component of the existing Federal Framework on AMR, which aims to promote innovation through funding collaborative research and development efforts on antimicrobial resistance both domestically and internationally as well as Tackling Antimicrobial Resistance and Antimicrobial Use: A Pan- Canadian Framework for Action.

This funding will contribute to moving the projects through the innovation pipeline and will facilitate their uptake to commercialization, direct application and/or equitable implementation in a healthcare setting. It will support projects led by academic researchers in collaboration with industry or other non-academic partners. Applicants will have acquired interest from partners willing to invest in the new/improved technology. The value of the partnership must be demonstrated.

 

Funds Available

The total amount available for this funding opportunity is $2,025,000, enough to fund approximately 3 grants. The maximum amount per grant is $225,000 per year for up to 3 years for a total of $675,000 per grant.

Applicants must secure eligible partner contributions (cash or in-kind) to match the CIHR contribution at a minimum of 1:1 ratio. These contributions must exclude any new or existing funding from any sources or grants from the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC), the Social Sciences and Humanities Research Council of Canada (SSHRC), the Networks of Centres of Excellence (NCE), and the Canada Research Chairs (CRC) program. As the intent of this phase 2 of POC diagnostics RFA is to bring/evaluate tests in clinical settings, the involvement of meaningful partners (cash and/or in-kind) is central. CIHR will recognize only those in-kind contributions detailed in the application and considered essential to carry out the work. It will be an integral part of the evaluation of the proposal.

NATIONAL GRANT OPPORTUNITY – The CIHR Institute of Genetics (CIHR-IG) and the CIHR Institute of Nutrition, Metabolism and Diabetes (INMD) in partnership with Genome Canada

Title: Other: Research Network: Rare Diseases

Sponsor: The CIHR Institute of Genetics (CIHR-IG) and the CIHR Institute of Nutrition, Metabolism and Diabetes (INMD) in partnership with Genome Canada

Funding Amount: The total amount available from CIHR for this funding opportunity is $1,120,000, in addition, up to $560,000 is being provided by Genome Canada, enough to fund one (1) national network. This amount may increase if additional funding partners participate.

The maximum amount to fund one (1) national network is $420,000 per year for up to 4 years.

Application Deadline: May 15, 2018

ORS Deadline: May 8, 2018

ORS Contact: Bryn Jones Square, Research Grants Office (CIHR), bryn.jonessquare@umanitoba.ca

Causative genes for human genetic disease are now being discovered at a remarkable rate. In some cases, these genes have well-known functions, but in many other cases, they have not been the subject of much previous study, and little or nothing is known about their function. As recognized in International Rare Diseases Research Consortium’s (IRDiRC) policies and guidelines, model organisms such as yeast, C. elegans, Drosophila, zebrafish, and mice, provide powerful and efficient tools to validate putative disease genes and to gain understanding about the functions of unknown genes. Canada has a great deal of fundamental research strength in these areas, and we have seen over the past few years the potential of collaboration between these research communities and clinical geneticists who are working directly with people who are living with rare genetic diseases.

This program builds on the success of the Research Catalyst Network: Rare Diseases program, launched in 2014, which led to the development of the Rare Diseases Models and Mechanisms Network (RDMM). Thanks in part to this network, the first of its kind around the globe, Canada’s national gene discovery programs are progressing at a higher success rate than anticipated, largely because of the international uptake of the Matchmaker Exchange initiative, which has accelerated the identification of additional families with the same rare disease. The current volume of novel genes waiting for a connection to a model organism expert continue to grow, thereby supporting the second launch of this program. Moreover, the RDMM inspired and supported the development of similar initiatives in other countries, and for about 10% of submitted genes, no suitable model could be identified in Canada. This second edition of the program therefore seeks to support a Rare Disease Network aiming at maintaining Canada’s leadership in enabling clinical geneticists who are identifying rare disease gene mutations to collaborate with model organism researchers with expertise in the cognate gene’s function, and to develop the capacity to study genes for which no suitable models can be identified in Canada or in other countries with similar networks. This will provide a powerful incentive for expanded international collaborations between Canadian model organism researchers and clinical geneticists elsewhere, and will enable reciprocal arrangements whereby model organism researchers elsewhere will be funded by other networks to collaborate with Canadian clinicians.

FELLOWSHIP FUNDING OPPORTUNITIES/ANNOUNCEMENTS: CSHP Fellow Program

Title: CSHP Fellow Program

Sponsor: Canadian Society of Hospital Pharmacists

Deadline: 02-Jul-2018

Contact Name: Pamela Saunders

Contact Telephone: 613-736-9733

Contact Email: psaunders@cshp.ca

Link: https://www.cshp.ca/fellows-program

The CSHP Fellow program was initiated 50 years ago to recognize members who, through their practice activities and contributions to CSHP and the profession, were worthy of a recognition that signified outstanding leadership, dedication and commitment to practice excellence and professional growth.

To date, 186 members of CSHP have achieved the distinction of being recognized as a “Fellow of the Canadian Society of Hospital Pharmacists” (FCSHP).

The Fellow program rewards the long term, sustained efforts of candidates in the areas that service the Society, patient care, education or research, and the profession. Candidates for Fellow status are assessed in a peer review process after completing an application form which documents the member's achievements in several key criteria areas.

This category of membership which is not intended to be merely a means of recognizing hospital pharmacists for their achievements and contribution to the profession, but rather a means of providing a stimulus and challenge for hospital pharmacists to raise standards of professional service and make hospital pharmacy an even more attractive specialty.

AWARDS- Canadian Orthopaedic Foundation - Community Innovation Award

Title: Community Innovation Award

Sponsor: Canadian Orthopaedic Foundation

Funding Amount: Two $15,000 awards are available in 2018 to be used by the recipients to further their research project with a duration of up to two years.

Application Deadline: June 30, 2018, 5:00 pm EST

ORS Deadline: June 22, 2018

ORS Contact: Michelina Violi, Research Grant Officer (Health), Michelina.Violi@umanitoba.ca

Link: http://whenithurtstomove.org/wp-content/uploads/2018-Community-Innovation-Award- Guidelines-EN.pdf

The Community Innovation Award celebrates community-based surgeons and research studies dedicated to improving patient care or musculoskeletal health in their community. These community surgeons are not full time academics, but may have an academic appointment to teach on an occasional basis. This program fills a gap in the research landscape in Canada, encouraging community orthopaedic researchers to bring their research ideas to fruition.

TRAVEL AWARDS – Canadian Institute of Health Research CIHR

Title:  International Course On Antibiotics And Resistance (ICARE) Travel Awards

Sponsor: CIHR

Application Deadline: May 15, 2018

ORS Deadline: May 8, 2018

ORS Contact: Bryn Jones Square, Research Grants Office (CIHR), bryn.jonessquare@umanitoba.ca

Funding Amount:  The total funds available for this funding opportunity is $9,900, enough to provide three (3) travel awards of up to $3,300 each.

Three travel awards will be provided in 2018-2019 for early-career scientists (post-doctoral fellows, post-health professional degree fellows and investigators) to attend

the International Course on Antibiotics and Resistance (ICARe) from October 6 to 14, 2018 at Les Pensières, Annecy, France.

Objectives

To provide travel awards to individuals in aid of research and knowledge translation activities consistent with CIHR III vision, mandate and strategic directions where the circumstances fall outside CIHR's current suite of funding programs.

To provide Canadian early-career scientists – PhD candidates, post-doctoral fellows, post-health professional degree fellows and investigators at an academic or research institution – the opportunity to emerge with a state-of-the-art understanding of existing antibiotics.

How to apply

Note that the application process is managed by ICARe. You will find the complete instructions for how to apply on the ICARe website.

 

George and Fay Yee Centre for Healthcare Innovation
Third floor, Chown Building
753 McDermot Avenue
Winnipeg, MB, Canada
R3E 0T6
Phone: 204.594.5391 Fax: 204.594.5394 Email:info@chimb.ca